High incidence of microscopic gastrointestinal stromal tumors in the stomach

Kawanowa, Kaori; Sakuma, Yoshiki; Sakurai, Shunsuke; Hishima, Tsunekazu; Iwasaki, Yoshiaki; Saito, Kana; Hosoya, Yoshinori; Nakajima, Takashi; Funata, Nobuaki

doi:10.1016/j.humpath.2006.07.002

Cited by 314 publications

(244 citation statements)

References 33 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…[79][80][81][82] These so-called micro-GISTs are mitotically inactive and often partially calcified, suggesting tumorigenic arrest. In contrast to the diffuse ICC hyperplasia observed in the presence of a germline KIT mutation, micro-GISTs appear to represent a nodular form of ICC overgrowth caused in most cases by local, somatic acquisition of a KIT mutation.…”

Section: Micro-gistsmentioning

confidence: 99%

Gastrointestinal stromal tumors: what do we know now?

2014

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract, arising from the interstitial cells of Cajal, primarily in the stomach and small intestine. They manifest a wide range of morphologies, from spindle cell to epithelioid, but are immunopositive for KIT (CD117) and/or DOG1 in essentially all cases. Although most tumors are localized at presentation, up to half will recur in the abdomen or spread to the liver. The growth of most GISTs is driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT (75% of cases) or PDGFRA (10%). Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib is effective in controlling unresectable disease; however, drug resistance caused by secondary KIT or PDGFRA mutations eventually develops in 90% of cases. Adjuvant therapy with imatinib is commonly used to reduce the likelihood of disease recurrence after primary surgery, and for this reason assessing the prognosis of newly resected tumors is one of the most important roles for pathologists. Approximately 15% of GISTs are negative for mutations in KIT and PDGFRA. Recent studies of these so-called wild-type GISTs have uncovered a number of other oncogenic drivers, including mutations in neurofibromatosis type I, RAS genes, BRAF, and subunits of the succinate dehydrogenase complex. Routine genotyping is strongly recommended for optimal management of GISTs, as the type and dose of TKI used for treatment is dependent on the mutation identified.

show abstract

Section: Micro-gistsmentioning

confidence: 99%

Gastrointestinal stromal tumors: what do we know now?

2014

View full text Add to dashboard Cite

show abstract

“…In the 1990´s, some inconsistencies in broad classification of tumors as GIST were reported. An important discovery was the identification of CD117 receptor expression for almost all GIST, unlike leiomyomas, leiomyosarcomas and other spindle cell tumors of the tract gastrointestinal that are often CD117 negative (5,6) . As described in the literature, the first acute symptom of this patient was gastrointestinal hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

“…As described in the literature, the first acute symptom of this patient was gastrointestinal hemorrhage. Bleeding is present in approximately 40% of cases (6,7) . DOG1 is a membrane protein discovered through analysis of the gene expression patterns of GIST, which showed to be a useful immunohistochemical marker (8) .…”

Section: Discussionmentioning

confidence: 99%

Hemoperitôneo secundário a GIST gástrico c-KIT negativo e anticorpo anti-DOG1 positivo

Epstein

Pasquetti

Costa

et al. 2012

Einstein (São Paulo)

View full text Add to dashboard Cite

Although relatively rare, the gastrointestinal stromal tumors comprise most mesenchymal tumors of the digestive tract and account for 5% of all sarcomas. The most common symptoms are pain, gastrointestinal bleeding and palpable mass. This study reported the case of a young patient who developed hemoperitoneum due to gastric neoplasm rupture and required urgent surgical treatment. Pathology and immunohistochemistry analysis showed an epidemiologically rare case: epithelioid and c-KIT negative tumor.Keywords: Gastrointestinal stromal tumors; Gastrointestinal hemorrhage/diagnosis; Gastrectomy; Gastrointestinal neoplasms; Endoscopy; Case reports RESUMOOs tumores estromais do trato gastrintestinal, embora relativamente raros, compreendem a maioria dos tumores mesenquimais do trato digestivo e constituem 5% de todos os sarcomas. Quanto à apresentação clínica, os sintomas mais comuns são dor, hemorragia digestiva e massa palpável. Este trabalho relatou o caso de um paciente jovem que desenvolveu hemoperitôneo por ruptura de neoplasia gástrica e necessitou de tratamento cirúrgico de urgência. A análise patológica e imunoistoquímica revelou tratar-se de um caso raro epidemiologicamente: tipo celular epitelioide e c-KIT negativo.

show abstract

“…Diğer semptom ve bulgulara bakıldığında anoreksi, kilo kaybı, mide bulantısı, gastrointestinal tıkanıklık veya obstrük-tif sarılık yer almaktadır. 1,2,9 Ancak bazı tümörler asemptomatik olup cerrahi sırasında tesadüfen rastlanılabilir. Bizim hastalarımızda da, karın ağrısı bü-tün hastalarda ortak başvuru semptomu olarak göze çarpmaktadır.…”

Section: Discussionunclassified

The clinical and histopathological presentations of patients with gastrointestinal stromal tumors

Ekız¹,

Ünverdǐ²,

Altınbaş³

et al. 2012

Dicle Med J

View full text Add to dashboard Cite

Objectives: Gastrointestinal stromal tumors (GIST) are originated from mesenchymal / stromal cells and are rarely seen in gastrointestinal tract. In this study, we aimed to determine the clinical and histopathological presentations, and tumor localizations of the patients with GIST. Materials and methods:Totally, 18 patients were included in the study. Ten patients were male (56%), and the mean age was 54.2 (30-75) years. Results:The most common sites of organs involved are stomach, peritonea, colon, small intestine, omentum and esophagus, respectively. The major symptom of the patients with GIST is abdominal pain. Distant organ metastasis was detected in 22.2% of the patients. Conclusion:We found that the most common presentation of patients with GIST is abdominal pain, and the most common involved organ is the stomach.

show abstract

High incidence of microscopic gastrointestinal stromal tumors in the stomach

Cited by 314 publications

References 33 publications

Gastrointestinal stromal tumors: what do we know now?

Gastrointestinal stromal tumors: what do we know now?

Hemoperitôneo secundário a GIST gástrico c-KIT negativo e anticorpo anti-DOG1 positivo

The clinical and histopathological presentations of patients with gastrointestinal stromal tumors

Contact Info

Product

Resources

About